{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:43:02Z","timestamp":1790718182370,"version":"4.1.0"},"reference-count":188,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>In recent years, the vital role of genetic factors in human diseases have been widely recognized by scholars with the deepening of life science research, accompanied by the rapid development of gene-editing technology. In early years, scientists used homologous recombination technology to establish gene knock-out and gene knock-in animal models, and then appeared the second-generation gene-editing technology zinc-finger nucleases (ZFNs) and transcription activator\u2013like effector nucleases (TALENs) that relied on nucleic acid binding proteins and endonucleases and the third-generation gene-editing technology that functioned through protein\u2013nucleic acids complexes\u2014CRISPR\/Cas9 system. This holds another promise for refractory diseases and genetic diseases. Cardiovascular disease (CVD) has always been the focus of clinical and basic research because of its high incidence and high disability rate, which seriously affects the long-term survival and quality of life of patients. Because some inherited cardiovascular diseases do not respond well to drug and surgical treatment, researchers are trying to use rapidly developing genetic techniques to develop initial attempts. However, significant obstacles to clinical application of gene therapy still exists, such as insufficient understanding of the nature of cardiovascular disease, limitations of genetic technology, or ethical concerns. This review mainly introduces the types and mechanisms of gene-editing techniques, ethical concerns of gene therapy, the application of gene therapy in atherosclerosis and inheritable cardiovascular diseases, in-stent restenosis, and delivering systems.<\/jats:p>","DOI":"10.3389\/fcvm.2021.760140","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T10:31:59Z","timestamp":1636108319000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects"],"prefix":"10.3389","volume":"8","author":[{"given":"Genmao","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhen","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1001\/jama.2017.4150","article-title":"Trends and patterns of geographic variation in cardiovascular mortality among US counties, 1980-2014","volume":"317","author":"Roth","year":"2017","journal-title":"Jama."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.ymthe.2018.08.007","article-title":"Correction of the marfan syndrome pathogenic fbn1 mutation by base editing in human cells and heterozygous embryos","volume":"26","author":"Zeng","year":"2018","journal-title":"Mol Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0960-8966(97)00051-5","article-title":"The scope of gene therapy in humans: scientific, safety and ethical considerations","volume":"7","author":"Karpati","year":"1997","journal-title":"Neuromuscul Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1111\/pbi.13383","article-title":"Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective","volume":"18","author":"Zhang","year":"2020","journal-title":"Plant Biotechnol J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3390\/ijms19041089","article-title":"Applications of CRISPR\/Cas system to bacterial metabolic engineering","volume":"19","author":"Cho","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature."},{"key":"B8","volume-title":"Human Genome Editing: Science, Ethics, and Governance.","year":"2017"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.gde.2018.05.002","article-title":"Ethical issues in genetic modification and why application matters","volume":"52","author":"Munsie","year":"2018","journal-title":"Curr Opin Genet Dev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev-med-112717-094629","article-title":"Ethics of human genome editing","volume":"70","author":"Coller","year":"2019","journal-title":"Annu Rev Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1053\/j.semperi.2018.09.003","article-title":"CRISPR\/Cas9 gene-editing: research technologies, clinical applications and ethical considerations","volume":"42","author":"Memi","year":"2018","journal-title":"Semin Perinatol."},{"key":"B12","volume-title":"Heritable Human Genome Editing","year":"2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jmb.2018.05.044","article-title":"CRISPR ethics: moral considerations for applications of a powerful tool","volume":"431","author":"Brokowski","year":"2019","journal-title":"J Mol Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"20180106","DOI":"10.1098\/rstb.2018.0106","article-title":"The ethics of genome editing in non-human animals: a systematic review of reasons reported in the academic literature","volume":"374","author":"de Graeff","year":"2019","journal-title":"Philos Trans R Soc Lond B Biol Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/mt.2012.284","article-title":"Generation of an HIV resistant T-cell line by targeted \u201cstacking\u201d of restriction factors","volume":"21","author":"Voit","year":"2013","journal-title":"Mol Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s43141-020-00078-y","article-title":"The genome editing revolution: review","volume":"18","author":"Khalil","year":"2020","journal-title":"J Genet Eng Biotechnol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.18609\/cgti.2017.005","article-title":"Recent advances in the use of ZFN-mediated gene editing for human gene therapy","volume":"3","author":"Chandrasegaran","year":"2017","journal-title":"Cell Gene Ther Insights."},{"key":"B18","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1073\/pnas.91.3.883","article-title":"Chimeric restriction endonuclease","volume":"91","author":"Kim","year":"1994","journal-title":"Proc Natl Acad Sci USA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.89.10.4275","article-title":"Functional domains in Fok I restriction endonuclease","volume":"89","author":"Li","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B20","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1126\/science.2028256","article-title":"Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A","volume":"252","author":"Pavletich","year":"1991","journal-title":"Science."},{"key":"B21","doi-asserted-by":"publisher","first-page":"10570","DOI":"10.1073\/pnas.95.18.10570","article-title":"FokI dimerization is required for DNA cleavage","volume":"95","author":"Bitinaite","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/mt.2008.233","article-title":"Expanding or restricting the target site repertoire of zinc-finger nucleases: the inter-domain linker as a major determinant of target site selectivity","volume":"17","author":"H\u00e4ndel","year":"2009","journal-title":"Mol Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1128\/MCB.15.4.1968","article-title":"Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae","volume":"15","author":"Choulika","year":"1995","journal-title":"Mol Cell Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5560","DOI":"10.1093\/nar\/gks179","article-title":"Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects","volume":"40","author":"Yonemitsu","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt1319","article-title":"An improved zinc-finger nuclease architecture for highly specific genome editing","volume":"25","author":"Miller","year":"2007","journal-title":"Nat Biotechnol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1534\/genetics.111.131433","article-title":"Genome engineering with zinc-finger nucleases","volume":"188","author":"Carroll","year":"2011","journal-title":"Genetics."},{"key":"B27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nbt.1755","article-title":"A TALE nuclease architecture for efficient genome editing","volume":"29","author":"Miller","year":"2011","journal-title":"Nat Biotechnol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1126\/science.1204094","article-title":"TAL effectors: customizable proteins for DNA targeting","volume":"333","author":"Bogdanove","year":"2011","journal-title":"Science."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1093\/nar\/gkr218","article-title":"Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting","volume":"39","author":"Cermak","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.tcb.2013.04.003","article-title":"TAL effectors: highly adaptable phytobacterial virulence factors and readily engineered DNA-targeting proteins","volume":"23","author":"Doyle","year":"2013","journal-title":"Trends Cell Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sbi.2012.11.001","article-title":"TAL effectors: function, structure, engineering and applications","volume":"23","author":"Mak","year":"2013","journal-title":"Curr Opin Struct Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung","year":"2013","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1093\/nar\/gks199","article-title":"Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers","volume":"40","author":"Bultmann","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/ncomms1962","article-title":"Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains","volume":"3","author":"Cong","year":"2012","journal-title":"Nat Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"11163","DOI":"10.1093\/nar\/gks875","article-title":"3rd. Chimeric TALE recombinases with programmable DNA sequence specificity","volume":"40","author":"Mercer","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00439-016-1678-2","article-title":"TALEN gene editing takes aim on HIV","volume":"135","author":"Benjamin","year":"2016","journal-title":"Hum Genet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","article-title":"Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product","volume":"169","author":"Ishino","year":"1987","journal-title":"J Bacteriol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1046\/j.1365-2958.2002.02839.x","article-title":"Identification of genes that are associated with DNA repeats in prokaryotes","volume":"43","author":"Jansen","year":"2002","journal-title":"Mol Microbiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu Rev Biophys"},{"key":"B40","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.1254445","article-title":"Prevention of muscular dystrophy in mice by CRISPR\/Cas9-mediated editing of germline DNA","volume":"345","author":"Long","year":"2014","journal-title":"Science."},{"key":"B42","doi-asserted-by":"publisher","first-page":"R40","DOI":"10.1093\/hmg\/ddu125","article-title":"CRISPR\/Cas9 for genome editing: progress, implications and challenges","volume":"23","author":"Zhang","year":"2014","journal-title":"Hum Mol Genet."},{"key":"B43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.cell.2020.12.017","article-title":"A natural single-guide RNA repurposes Cas9 to autoregulate CRISPR-Cas expression","volume":"184","author":"Workman","year":"2021","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/bs.pmbts.2020.12.012","article-title":"History, evolution and classification of CRISPR-Cas associated systems","volume":"179","author":"Agarwal","year":"2021","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","article-title":"Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing","volume":"35","author":"Yin","year":"2017","journal-title":"Nat Biotechnol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"12009","DOI":"10.1038\/ncomms12009","article-title":"Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity","volume":"7","author":"Nguyen","year":"2016","journal-title":"Nat Commun."},{"key":"B47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.molcel.2017.09.029","article-title":"Methods and applications of CRISPR-mediated base editing in eukaryotic genomes","volume":"68","author":"Hess","year":"2017","journal-title":"Mol Cell."},{"key":"B48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.chembiol.2015.12.009","article-title":"Chemical biology approaches to genome editing: understanding, controlling, and delivering programmable nucleases","volume":"23","author":"Hu","year":"2016","journal-title":"Cell Chem Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.stem.2013.10.016","article-title":"Correction of a genetic disease in mouse via use of CRISPR-Cas9","volume":"13","author":"Wu","year":"2013","journal-title":"Cell Stem Cell."},{"key":"B50","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature."},{"key":"B51","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature."},{"key":"B52","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos","volume":"364","author":"Zuo","year":"2019","journal-title":"Science."},{"key":"B53","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nbt.4199","article-title":"An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities","volume":"36","author":"Gehrke","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nbt.4172","article-title":"Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction","volume":"36","author":"Koblan","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41587-020-0414-6","article-title":"Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors","volume":"38","author":"Doman","year":"2020","journal-title":"Nat Biotechnol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/s41587-020-0527-y","article-title":"Dual base editor catalyzes both cytosine and adenine base conversions in human cells","volume":"38","author":"Zhang","year":"2020","journal-title":"Nat Biotechnol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41587-020-0535-y","article-title":"A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing","volume":"38","author":"Grunewald","year":"2020","journal-title":"Nat Biotechnol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature."},{"key":"B59","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41586-020-03086-7","article-title":"In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice","volume":"589","author":"Koblan","year":"2021","journal-title":"Nature."},{"key":"B61","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.addr.2020.02.003","article-title":"Therapeutic genome editing in cardiovascular diseases","volume":"168","author":"Nishiga","year":"2021","journal-title":"Adv Drug Deliv Rev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/cvr\/cvv205","article-title":"Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation","volume":"108","author":"Rincon","year":"2015","journal-title":"Cardiovasc Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In vivo AAV-CRISPR\/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation."},{"key":"B64","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"Jama."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week","volume":"72","author":"Libby","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B67","first-page":"Ii47","article-title":"Atherosclerotic plaque rupture and thrombosis. Evolving concepts","volume":"82","author":"Fuster","year":"1990","journal-title":"Circulation"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000725","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation."},{"key":"B69","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo-brief report","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/eurheartj\/ehx373","article-title":"Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke","volume":"39","author":"Hopewell","year":"2018","journal-title":"Eur Heart J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12944-019-1166-5","article-title":"Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease","volume":"18","author":"Dai","year":"2019","journal-title":"Lipids Health Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"lqz012","DOI":"10.1093\/nargab\/lqz012","article-title":"Losses of human disease-associated genes in placental mammals","volume":"2","author":"Sharma","year":"2020","journal-title":"NAR Genom Bioinform"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/01.ATV.0000255311.26383.2f","article-title":"A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol","volume":"27","author":"Fasano","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1210\/jc.2016-1206","article-title":"PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis","volume":"101","author":"Langsted","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"B76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nrcardio.2017.67","article-title":"Genetics: ANGPTL3 deficiency protects from CAD","volume":"14","author":"Fern\u00e1ndez-Ruiz","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrcardio.2014.99","article-title":"Genetics. APOC3 mutations lower CVD risk","volume":"11","author":"Geach","year":"2014","journal-title":"Nat Rev Cardiol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1161\/ATVBAHA.118.311476","article-title":"Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism","volume":"39","author":"Reyes-Soffer","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1051\/medsci\/200420121068","article-title":"PCSK9: a new gene involved in familial hypercholesteremia","volume":"20","author":"Lambert","year":"2004","journal-title":"Med Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2016.06.011","article-title":"A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification","volume":"251","author":"Goettsch","year":"2016","journal-title":"Atherosclerosis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1161\/ATVBAHA.116.307613","article-title":"Hypercholesterolemia induced by a PCSK9 gain-of-function mutation augments angiotensin II-induced abdominal aortic aneurysms in C57BL\/6 mice-brief report","volume":"36","author":"Lu","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1161\/JAHA.117.006207","article-title":"Ossabaw pigs with a PCSK9 gain-of-function mutation develop accelerated coronary atherosclerotic lesions: a novel model for preclinical studies","volume":"7","author":"Yuan","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B87","doi-asserted-by":"publisher","first-page":"12404","DOI":"10.1002\/anie.201903618","article-title":"Triple-targeting delivery of CRISPR\/Cas9 to reduce the risk of cardiovascular diseases","volume":"58","author":"Zhang","year":"2019","journal-title":"Angew Chem Int Ed Engl."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/cvr\/cvy128","article-title":"PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature."},{"key":"B94","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature."},{"key":"B95","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/cvr\/cvv192","article-title":"Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII","volume":"107","author":"Li","year":"2015","journal-title":"Cardiovasc Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.cmet.2010.09.001","article-title":"Regulation of hepatic ApoC3 expression by PGC-1\u03b2 mediates hypolipidemic effect of nicotinic acid","volume":"12","author":"Hernandez","year":"2010","journal-title":"Cell Metab."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317686","article-title":"Inactivation of ApoC3 by CRISPR\/Cas9 Protects Against Atherosclerosis in Hamsters","volume":"127","author":"Guo","year":"2020","journal-title":"Circ Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: the diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1161\/ATVBAHA.109.191379","article-title":"Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano","volume":"29","author":"Alexander","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat Rev Cardiol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.plipres.2012.03.003","article-title":"Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?","volume":"51","author":"Otocka-Kmiecik","year":"2012","journal-title":"Prog Lipid Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1161\/ATVBAHA.116.308258","article-title":"Local vascular gene therapy with apolipoprotein A-I. to promote regression of atherosclerosis","volume":"37","author":"Wacker","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/ATVBAHA.107.158998","article-title":"Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men","volume":"28","author":"Rigamonti","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.7150\/thno.26193","article-title":"Sonodynamic therapy-induced foam cells apoptosis activates the phagocytic PPARgamma-LXRalpha-ABCA1\/ABCG1 pathway and promotes cholesterol efflux in advanced plaque","volume":"8","author":"Wang","year":"2018","journal-title":"Theranostics."},{"key":"B105","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1089\/hum.2007.0142","article-title":"Peroxisome proliferator-activated receptor-gamma1 gene therapy attenuates atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice","volume":"19","author":"Hu","year":"2008","journal-title":"Hum Gene Ther."},{"key":"B106","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/cvr\/cvu237","article-title":"Secretoneurin gene therapy improves hind limb and cardiac ischaemia in Apo E(-)\/(-) mice without influencing systemic atherosclerosis","volume":"105","author":"Theurl","year":"2015","journal-title":"Cardiovasc Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.CIR.0000038140.80105.AD","article-title":"Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice","volume":"106","author":"Inoue","year":"2002","journal-title":"Circulation."},{"key":"B108","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11883-012-0239-y","article-title":"receptors, atherosclerosis and inflammation","volume":"14","author":"Michael","year":"2012","journal-title":"Curr Atheroscler Rep."},{"key":"B109","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/gt.2011.29","article-title":"Macrophage LXRalpha gene therapy ameliorates atherosclerosis as well as hypertriglyceridemia in LDLR(-\/-) mice","volume":"18","author":"Li","year":"2011","journal-title":"Gene Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"107744","DOI":"10.1016\/j.pharmthera.2020.107744","article-title":"Long noncoding RNAs: potential therapeutic targets in cardiocerebrovascular diseases","volume":"221","author":"Zhang","year":"2021","journal-title":"Pharmacol Ther."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1055\/s-0039-1692680","article-title":"Long noncoding RNAs of the arterial wall as therapeutic agents and targets in atherosclerosis","volume":"119","author":"Holdt","year":"2019","journal-title":"Thromb Haemost."},{"key":"B112","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40291-019-00427-9","article-title":"The long non-coding RNA landscape of atherosclerotic plaques","volume":"23","author":"Kraczkowska","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"B113","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12929-020-00647-w","article-title":"Expedition to the missing link: long noncoding RNAs in cardiovascular diseases","volume":"27","author":"Yeh","year":"2020","journal-title":"J Biomed Sci."},{"key":"B114","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/nature17674","article-title":"Feedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXis","volume":"534","author":"Sallam","year":"2016","journal-title":"Nature."},{"key":"B115","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/CIRCULATIONAHA.117.029002","article-title":"Long noncoding RNA facilitated gene therapy reduces atherosclerosis in a murine model of familial hypercholesterolemia","volume":"136","author":"Tontonoz","year":"2017","journal-title":"Circulation."},{"key":"B116","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nrcardio.2010.30","article-title":"Marfan syndrome. Part 1: pathophysiology and diagnosis","volume":"7","author":"Ca\u00f1adas","year":"2010","journal-title":"Nat Rev Cardiol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1074\/jbc.M209256200","article-title":"Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein","volume":"278","author":"Isogai","year":"2003","journal-title":"J Biol Chem."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1161\/01.CIR.94.11.2708","article-title":"Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms","volume":"94","author":"Milewicz","year":"1996","journal-title":"Circulation."},{"key":"B119","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/cge.12702","article-title":"Pathogenic FBN1 variants in familial thoracic aortic aneurysms and dissections","volume":"89","author":"Regalado","year":"2016","journal-title":"Clin Genet."},{"key":"B120","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0014-4827(86)90038-8","article-title":"Transforming growth factor beta alters plasminogen activator activity in human skin fibroblasts","volume":"164","author":"Laiho","year":"1986","journal-title":"Exp Cell Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3892\/ijo.25.5.1375","article-title":"TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells","volume":"25","author":"Kim","year":"2004","journal-title":"Int J Oncol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/sj.ejhg.5201851","article-title":"Marfan syndrome: clinical diagnosis and management","volume":"15","author":"Dean","year":"2007","journal-title":"Eur J Hum Genet."},{"key":"B123","doi-asserted-by":"publisher","first-page":"102434","DOI":"10.1016\/j.scr.2021.102434","article-title":"Generation of genetically modified human induced pluripotent stem cell lines harboring haploin sufficient or dominant negative variants in the FBN1 gene","volume":"54","author":"Borsoi","year":"2021","journal-title":"Stem Cell Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"24413","DOI":"10.1038\/srep24413","article-title":"Generation of heterozygous fibrillin-1 mutant cloned pigs from genome-edited foetal fibroblasts","volume":"6","author":"Umeyama","year":"2016","journal-title":"Sci Rep."},{"key":"B125","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/gim.2014.11","article-title":"Loeys-Dietz syndrome: a primer for diagnosis and management","volume":"16","author":"MacCarrick","year":"2014","journal-title":"Genet Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/ng.2421","article-title":"Mutations in the TGF-\u03b2 repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm","volume":"44","author":"Doyle","year":"2012","journal-title":"Nat Genet."},{"key":"B127","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1056\/NEJMoa055695","article-title":"Aneurysm syndromes caused by mutations in the TGF-beta receptor","volume":"355","author":"Loeys","year":"2006","journal-title":"N Engl J Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/ng1511","article-title":"A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2","volume":"37","author":"Loeys","year":"2005","journal-title":"Nat Genet."},{"key":"B129","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/ng.2349","article-title":"Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm","volume":"44","author":"Lindsay","year":"2012","journal-title":"Nat Genet."},{"key":"B130","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/ng.2348","article-title":"TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome","volume":"44","author":"Boileau","year":"2012","journal-title":"Nat Genet."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1161\/ATVBAHA.120.313033","article-title":"In vitro lineage-specific differentiation of vascular smooth muscle cells in response to SMAD3 deficiency: implications for SMAD3-related thoracic aortic aneurysm","volume":"40","author":"Gong","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"e63545","DOI":"10.7554\/eLife.63545","article-title":"Mutations in SKI in Shprintzen-Goldberg syndrome lead to attenuated TGF-\u03b2 responses through SKI stabilization","volume":"10","author":"Gori","year":"2021","journal-title":"Elife"},{"key":"B133","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.jacc.2018.04.089","article-title":"Clinical validity of genes for heritable thoracic aortic aneurysm and dissection","volume":"72","author":"Renard","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cjca.2018.08.027","article-title":"A novel cause of familial hypercholesterolemia: PCSK9 gene duplication","volume":"34","author":"Paquette","year":"2018","journal-title":"Can J Cardiol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"3rd, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/MOL.0000000000000677","article-title":"Homozygous familial hypercholesterolemia: what treatments are on the horizon?","volume":"31","author":"Bajaj","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J Clin Invest."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1161\/CIRCULATIONAHA.119.040629","article-title":"Phenotypically silent bone morphogenetic protein receptor 2 mutations predispose rats to inflammation-induced pulmonary arterial hypertension by enhancing the risk for neointimal transformation","volume":"140","author":"Tian","year":"2019","journal-title":"Circulation."},{"key":"B139","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/CIRCRESAHA.115.303404","article-title":"The genetics of pulmonary arterial hypertension","volume":"115","author":"Austin","year":"2014","journal-title":"Circ Res."},{"key":"B140","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension","volume":"26","author":"Lane","year":"2000","journal-title":"Nat Genet."},{"key":"B141","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J Clin Invest."},{"key":"B143","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1165\/rcmb.2013-0100OC","article-title":"Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension","volume":"49","author":"Drake","year":"2013","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1093\/hmg\/ddt216","article-title":"The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations","volume":"22","author":"Dunmore","year":"2013","journal-title":"Hum Mol Genet."},{"key":"B145","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1183\/09031936.00187310","article-title":"Targeted gene delivery of BMPR2 attenuates pulmonary hypertension","volume":"39","author":"Reynolds","year":"2012","journal-title":"Eur Respir J."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1164\/rccm.201510-1955OC","article-title":"A selective transforming growth factor-\u03b2 ligand trap attenuates pulmonary hypertension","volume":"194","author":"Yung","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1164\/rccm.201705-0923LE","article-title":"Transforming growth factor \u03b21- and bone morphogenetic protein 2\/PPAR\u03b3-regulated MicroRNAs in pulmonary arterial hypertension","volume":"196","author":"Calvier","year":"2017","journal-title":"Am J Respir Crit Care Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1161\/CIRCULATIONAHA.116.023381","article-title":"Extracellular matrix proteomics reveals interplay of aggrecan and aggrecanases in vascular remodeling of stented coronary arteries","volume":"137","author":"Suna","year":"2018","journal-title":"Circulation."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1161\/01.ATV.0000037100.44766.5B","article-title":"Inflammation and restenosis in the stent era","volume":"22","author":"Welt","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1161\/CIRCULATIONAHA.105.571315","article-title":"Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury","volume":"112","author":"Wang","year":"2005","journal-title":"Circulation."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1161\/01.CIR.0000019071.72887.BD","article-title":"Morphological predictors of restenosis after coronary stenting in humans","volume":"105","author":"Farb","year":"2002","journal-title":"Circulation."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1161\/ATVBAHA.115.306962","article-title":"Activation of peroxisome proliferator-activated receptor-\u03b4 as novel therapeutic strategy to prevent in-stent restenosis and stent thrombosis","volume":"36","author":"Hyt\u00f6nen","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biomaterials.2016.02.008","article-title":"Enhanced biocompatibility of CD47-functionalized vascular stents","volume":"87","author":"Slee","year":"2016","journal-title":"Biomaterials."},{"key":"B154","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1517\/17425247.2016.1144589","article-title":"Advances in stent-mediated gene delivery","volume":"13","author":"Adeel","year":"2016","journal-title":"Expert Opin Drug Deliv."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41551-021-00705-0","article-title":"Exosome-eluting stents for vascular healing after ischaemic injury","volume":"5","author":"Hu","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"B156","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/eurheartj\/ehv205","article-title":"Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment","volume":"36","author":"Otsuka","year":"2015","journal-title":"Eur Heart J."},{"key":"B157","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2013.06.002","article-title":"Modulation of NO and ROS production by AdiNOS transduced vascular cells through supplementation with L-Arg and BH4: implications for gene therapy of restenosis","volume":"230","author":"Forbes","year":"2013","journal-title":"Atherosclerosis."},{"key":"B158","doi-asserted-by":"publisher","first-page":"e0059420","DOI":"10.1128\/MCB.00594-20","article-title":"Genomic landscapes of noncoding RNAs regulating VEGFA and VEGFC expression in endothelial cells","volume":"41","author":"Mushimiyimana","year":"2021","journal-title":"Mol Cell Biol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ymthe.2004.02.020","article-title":"Potent inhibition of arterial intimal hyperplasia by TIMP1 gene transfer using AAV vectors","volume":"9","author":"Ramirez Correa","year":"2004","journal-title":"Mol Ther."},{"key":"B160","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1161\/01.CIR.0000018603.67989.71","article-title":"Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits","volume":"105","author":"Mori","year":"2002","journal-title":"Circulation."},{"key":"B161","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nm0695-541","article-title":"Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo","volume":"1","author":"Indolfi","year":"1995","journal-title":"Nat Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1161\/hc4601.099405","article-title":"Adenovirus-mediated gene transfer of a secreted transforming growth factor-beta type II receptor inhibits luminal loss and constrictive remodeling after coronary angioplasty and enhances adventitial collagen deposition","volume":"104","author":"Kingston","year":"2001","journal-title":"Circulation."},{"key":"B163","doi-asserted-by":"publisher","first-page":"112068","DOI":"10.1016\/j.colsurfb.2021.112068","article-title":"A two-pronged approach to regulate the behaviors of ECs and SMCs by the dual targeting-nanoparticles","volume":"208","author":"Wang","year":"2021","journal-title":"Colloids Surf B Biointerfaces."},{"key":"B164","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/01.RES.82.2.147","article-title":"Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo","volume":"82","author":"Yonemitsu","year":"1998","journal-title":"Circ Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/01.ATV.17.5.898","article-title":"Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo","volume":"17","author":"Ueno","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","article-title":"Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps","volume":"79","author":"Grieger","year":"2005","journal-title":"J Virol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","article-title":"Quantitative analysis of the packaging capacity of recombinant adeno-associated virus","volume":"7","author":"Dong","year":"1996","journal-title":"Hum Gene Ther."},{"key":"B168","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.hoc.2017.06.007","article-title":"Nonintegrating gene therapy vectors","volume":"31","author":"Athanasopoulos","year":"2017","journal-title":"Hematol Oncol Clin North Am."},{"key":"B169","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol Ther."},{"key":"B170","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature13902","article-title":"In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR\/Cas9 system","volume":"516","author":"Maddalo","year":"2014","journal-title":"Nature."},{"key":"B171","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/hum.2015.087","article-title":"Adenovirus-mediated somatic genome editing of Pten by CRISPR\/Cas9 in mouse liver in spite of Cas9-specific immune responses","volume":"26","author":"Wang","year":"2015","journal-title":"Hum Gene Ther."},{"key":"B172","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.2951","article-title":"Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing","volume":"32","author":"Heckl","year":"2014","journal-title":"Nat Biotechnol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-Cas9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell."},{"key":"B174","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2174\/15665232113136660005","article-title":"General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination","volume":"13","author":"Baldo","year":"2013","journal-title":"Curr Gene Ther."},{"key":"B175","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41417-019-0141-7","article-title":"Liposomal delivery of CRISPR\/Cas9","volume":"27","author":"Zhen Li","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1700611","DOI":"10.1002\/advs.201700611","article-title":"Exosome-liposome hybrid nanoparticles deliver CRISPR\/Cas9 system in MSCs","volume":"5","author":"Lin","year":"2018","journal-title":"Adv Sci."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1703036","DOI":"10.1002\/adfm.201703036","article-title":"Targeted delivery of CRISPR\/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles","volume":"27","author":"Chen","year":"2017","journal-title":"Adv Funct Mater"},{"key":"B178","doi-asserted-by":"publisher","first-page":"4903","DOI":"10.1073\/pnas.1712963115","article-title":"Nonviral gene editing via CRISPR\/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide","volume":"115","author":"Wang","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B179","doi-asserted-by":"publisher","first-page":"e1803061","DOI":"10.1002\/smll.201803061","article-title":"Fluorinated acid-labile branched hydroxyl-rich nanosystems for flexible and robust delivery of plasmids","volume":"14","author":"Qi","year":"2018","journal-title":"Small."},{"key":"B180","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.1038\/srep04513","article-title":"Validation of microinjection methods for generating knockout mice by CRISPR\/Cas-mediated genome engineering","volume":"4","author":"Horii","year":"2014","journal-title":"Sci Rep."},{"key":"B181","doi-asserted-by":"publisher","first-page":"11406","DOI":"10.1038\/srep11406","article-title":"Genome-editing via Oviductal Nucleic Acids Delivery system: a novel microinjection independent genome engineering method in mice","volume":"5","author":"Takahashi","year":"2015","journal-title":"Sci Rep."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"key":"B183","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.3390\/ijms21186494","article-title":"Definition of a novel plasmid-based gene transfection protocol of mammalian skeletal muscles by means of in vivo electroporation","volume":"21","author":"Spugnini","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B184","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/ncomms1568","article-title":"Genetic dissection of axon regeneration via in vivo electroporation of adult mouse sensory neurons","volume":"2","author":"Saijilafu Hur","year":"2011","journal-title":"Nat Commun"},{"key":"B185","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1161\/01.CIR.89.1.13","article-title":"Liposome-mediated gene transfer into human vascular smooth muscle cells","volume":"89","author":"Pickering","year":"1994","journal-title":"Circulation."},{"key":"B186","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1006\/mthe.2000.0053","article-title":"Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo","volume":"1","author":"Armeanu","year":"2000","journal-title":"Mol Ther."},{"key":"B187","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.1002\/adma.201602319","article-title":"PGMA-based star-like polycations with plentiful hydroxyl groups act as highly efficient miRNA delivery nanovectors for effective applications in heart diseases","volume":"28","author":"Li","year":"2016","journal-title":"Adv Mater"},{"key":"B188","doi-asserted-by":"publisher","first-page":"1900386","DOI":"10.1002\/advs.201900386","article-title":"CRISPR\/Cas9 delivery mediated with hydroxyl-rich nanosystems for gene editing in aorta","volume":"6","author":"Zhang","year":"2019","journal-title":"Adv Sci."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.760140\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T10:32:06Z","timestamp":1636108326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.760140\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":188,"alternative-id":["10.3389\/fcvm.2021.760140"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.760140","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]},"article-number":"760140"}}